| 查看: 1906 | 回复: 0 | ||||
[交流]
成都先导化学1类新药获批临床，新型HDAC I/IIb亚型选择性小分子抑制剂HG146
|
|
中国成都 2018年5月7日，成都先导今日宣布，公司已收到中国食品药品监督管理局（CFDA）核发的新型HDAC I/IIb亚型选择性小分子抑制剂HG146针对多发性骨髓瘤适应症的1类新药临床批件。 HG146是成都先导利用其核心技术平台DNA编码化合物库技术自主开发，拥有全新分子骨架结构的组蛋白去乙酰化酶（HDAC）I/IIb亚型选择性抑制剂。临床前研究结果证明其具有合理的药效和临床前安全性，与目前针对此类靶点的上市药物相比，展示出更好的有效性和安全性，并且具有肿瘤免疫治疗方面的潜力。 “我们将快速推进HG146的临床研究，希望该药物能够顺利早日使罹患疾病的病人受益。同时，成都先导将对核心技术平台DNA编码化合物库技术进行持续不断的创新，与合作伙伴一起利用这一技术产生更多的新药，满足更多的未满足临床需求。”成都先导董事长兼CEO李进博士如是说。 关于HG146 HG146主要通过上调细胞内组蛋白和微管蛋白乙酰化水平，调节抑癌基因的表达，并扰乱癌细胞内的蛋白稳态，诱发癌细胞凋亡。通过选择性地抑制HDAC I/IIb亚型，HG146能够抑制与多发性骨髓瘤的预后密切相关的信号通路，实现其抗肿瘤生物效应，同时降低了分子水平上可能存在的副作用。 关于多发性骨髓瘤 多发性骨髓瘤（Multiple myeloma, MM）是一种浆细胞（即效应B细胞）不正常增生，并侵犯骨髓的恶性肿瘤，至今仍是一种无法治愈的疾病。当浆细胞发生恶性癌变时，变为骨髓癌细胞（Myeloma cell），这些细胞倾向于聚集在骨髓内或骨外侧两端的坚硬部分，形成多个肿瘤病灶。多发性骨髓瘤会引发蚀骨细胞活化，导致骨骼外部的硬骨被破坏，引发骨骼疼痛、高钙血症、贫血、肾脏损害等症状。多发性骨髓瘤大多数患者的年龄在50岁以上，男女比例约为1.6：1。全球每年约有48.8万多发性骨髓瘤患者，并导致约10.1万人死亡。根据2017年中国国内的统计数据，多发性骨髓瘤在中国的发病率约为每10万人中2-3人，每年新增病例约2万人，总患者数估计超过10万人。根据2017年美国国内的统计数据，该疾病在美国的发病率约为每10万人中6.5人，占美国当年所有癌症病例的1.8%，约有30280例新确诊病例，以及约12590例患者死亡。 关于成都先导 成都先导是一家从事新药研发的生物技术公司。总部位于中国成都，在美国设有子公司。成都先导已建立了一个独特的早期新药发现平台，即DNA编码化合物库设计合成与筛选技术。目前，成都先导基于数百种不同的骨架结构，已经完成逾千亿结构全新、具有多样性和类药性DNA编码化合物的合成，并且已有多个案例证实了其针对已知靶点和新兴靶点筛选苗头化合物的能力。成都先导已与50余家制药、生物技术企业以及研究机构建立合作，致力于发现、开发新的治疗方案。 更多信息请访问：www.hitgen.com 获取更多信息，请联系： 李进博士，董事长兼CEO，成都先导药物开发有限公司，电话：+86 28 85197385(分机 8001) HitGen’s Small Molecule IND Receives Approval by CFDA for Clinical Trials Chengdu, China, May 7, 2018– HitGen Ltd. announced that its novel small molecule Class I/IIb HDAC inhibitor HG146 (Category 1 of new chemical drug) received approval by Chinese Food and Drug Administration (CFDA) to begin the clinical trials for Multiple Myeloma. HG146 is a self-developed Class I/IIb HDAC inhibitor with novel chemical scaffold developed from HitGen’s proprietary DNA Encoded Library technology. Comparing with the current listed HDAC inhibitors for multiple myeloma, its preclinical studies showed better efficacy and safety profile with potential application in immuno-oncology. “With this CFDA approval, we aim to start the clinical trials of HG146 as soon as possible. Meanwhile, we will continue to innovate and improve our core platform of DNA Encoded Libraries, in order to bring more new medicines to patients while collaborating with our partners and satisfying unmet clinical needs.” said Dr. Jin Li, Chairman and Chief Executive Officer of HitGen. About HG146 In preclinical studies, HG146 has been shown to upregulate the acetylation level of histone and tubulin, modulating the expression of tumor-suppressing genes and disrupting the protein homeostasis in cancer cells to induce apoptosis. By selectively inhibiting Class I/IIb HDAC, HG146 can inhibit the critical signaling pathways related to the prognosis of multiple myeloma and realize its antitumor biological effects while reducing potential side effects. About Multiple Myeloma Multiple Myeloma (MM) is a type of neoplasm formed by malignant plasma cells, which still remains an unmet medical need. Through a complex, multi-step process, healthy plasma cells transform into malignant myeloma cells developing in the soft, spongy tissue within bone marrow or two sides of bones to form multiple tumor lesions. MM will cause osteocyte activation, damage os osseum to further trigger osteodynia, hypercalcemia, anaemia, kidney damage, etc. The average age of patients suffering from MM is above 50 with the ratio of male to female 1.6:1. There are about 488,000 patients annually worldwide and about 100,000 of them will lose their lives. According to China’s 2017 statistics, the incidence of MM in China is about 2-3 out of 100,000 people with 20,000 new cases annually. Meanwhile, the incidence of MM in US is about 6.5 out of 100,000 people accounting for 1.8% of all cancer cases in 2017, with 30,280 new cases and 12,590 death. About HitGen Ltd. HitGen is a biotech company with headquarters and main research facilities based in Chengdu, China and with a subsidiary in the USA. HitGen has established a platform for small molecular discovery centred around DNA encoded chemical libraries (DELs). HitGen’s DELs contain more than 100 billion novel, diverse, drug-like small molecule and macrocyclic compounds. These compounds are members of DELs synthesised from many hundreds of distinct chemical scaffolds, designed with tractable chemistry, and yielding proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. HitGen is collaborating with over 50 pharmaceutical, biotech, and chemical companies and research institutes in Asia, North America and Europe to discover and develop approaches for novel medicines. For more information, you may visit www.hitgen.com |
回复此楼» 收录本帖的淘帖专辑推荐
 DNA编码化合物库 |
» 猜你喜欢
如何高效的测量腺病毒的粒径和电位
已经有0人回复
-
26在职申博—生物与医药—抗体/ADC药物方向，江浙沪，有项目，可带资。
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有300人回复
-
288分求调剂
已经有0人回复
-
一志愿苏州大学 生物技术与工程（086001） 初试323分，求调剂
已经有0人回复
-
三年实验室工作经历，一志愿华中农业大学微生物，总分288求调剂
已经有5人回复
-
070700求调剂
已经有1人回复
-
求调剂总分327
已经有1人回复
-
BL21(DE3)UV或者丝裂霉素诱导条件下会释放DE3的噬菌体吗？
已经有14人回复
-
随访时间怎么确定
已经有0人回复
» 本主题相关商家推荐: (我也要在这里推广)
5